Literature DB >> 25129201

Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability.

Syed Imran Haider1, Zahid Ansari2, Loretta Vaughan3, Helen Matters4, Eric Emerson5.   

Abstract

Although polypharmacy is a medication safety concern leading to increased risk of non-adherence, adverse drug reaction and drug-drug interactions, polypharmacy and associated risk factors has rarely been investigated involving people with ID at a population level. The purpose of this paper is to analyze the prevalence of polypharmacy and to evaluate the role of different factors associated with polypharmacy in a state-wide representative population of adults with ID. In a population-based survey in Victoria, Australia, 897 people with ID 18 years of age or older were selected by simple random sampling. The data were collected from proxy respondents on behalf of people with ID. Polypharmacy was defined as the concomitant use of five or more medications. The data were weighted to reflect the age/sex/geographic distribution of the population. Results revealed that more than 76% of adults with ID had used prescribed medicine and about 21% were exposed to polypharmacy in the last two weeks. In both univariate and multivariate analyses, polypharmacy was significantly associated with older age, unemployment and inability to get help from family and friends if needed. After controlling for age, sex and severity of intellectual disability, polypharmacy was associated with having a blood pressure, blood cholesterol and blood glucose level check. Polypharmacy was also associated with a greater number of visits to general practitioners, fair or poor reported health status and inability to walk unaided. Subjects with epilepsy, diabetes, stroke, osteoporosis and cancer had a higher probability of polypharmacy. None of the disease inducing behaviors was associated with polypharmacy. This study highlights the need that medication should be regularly reviewed overall in ID population and particularly when polypharmacy exists.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Developmental disability; Intellectual disability; Medicine use; Pharmacoepidemiology; Polypharmacy

Mesh:

Year:  2014        PMID: 25129201     DOI: 10.1016/j.ridd.2014.07.060

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  14 in total

Review 1.  Managing complexity in care of patients with intellectual and developmental disabilities: Natural fit for the family physician as an expert generalist.

Authors:  Elizabeth Grier; Dara Abells; Ian Casson; Meg Gemmill; Jessica Ladouceur; Amanda Lepp; Ullanda Niel; Samantha Sacks; Kyle Sue
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

2.  Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

Review 3.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

4.  Prevalence and Covariates of Polypharmacy in Elderly Patients on Discharge from a Tertiary 
Care Hospital in Oman.

Authors:  Amna Al-Hashar; Hamed Al Sinawi; Anwar Al Mahrizi; Manal Al-Hatrushi
Journal:  Oman Med J       Date:  2016-11

5. 

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

6.  Polypharmacy influences the renal composite outcome in patients treated with sodium-glucose cotransporter 2 inhibitors.

Authors:  Kazuo Kobayashi; Masao Toyoda; Nobuo Hatori; Takayuki Furuki; Hiroyuki Sakai; Yutaka Hatori; Kazuyoshi Sato; Masaaki Miyakawa; Kouichi Tamura; Akira Kanamori
Journal:  Clin Transl Sci       Date:  2022-01-12       Impact factor: 4.438

7.  Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.

Authors:  Prajwal Dhakal; Elizabeth Lyden; Kate-Lynn E Muir; Zaid S Al-Kadhimi; Thuy Koll; Lori J Maness; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Leuk Lymphoma       Date:  2020-03-11

8.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

9.  The physical health of British adults with intellectual disability: cross sectional study.

Authors:  Eric Emerson; Chris Hatton; Susannah Baines; Janet Robertson
Journal:  Int J Equity Health       Date:  2016-01-20

Review 10.  What is polypharmacy? A systematic review of definitions.

Authors:  Nashwa Masnoon; Sepehr Shakib; Lisa Kalisch-Ellett; Gillian E Caughey
Journal:  BMC Geriatr       Date:  2017-10-10       Impact factor: 4.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.